Press Release

Category Added in a WPeMatico Campaign

Business Wire20 April 2026

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer

Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and…
Read More »
Business Wire20 April 2026

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer

Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and…
Read More »
Cision PR Newswire20 April 2026

Milvus Robotics Introduces the SEIT F1500S Forklift-Type Autonomous Mobile Robot for Advanced Material Handling

ATLANTA, April 20, 2026 /PRNewswire/ — Milvus Robotics has officially introduced its latest advancement in industrial automation, the SEIT F1500S, a…
Read More »
Cision PR Newswire20 April 2026

Daqo New Energy Files Annual Report on Form 20-F for Fiscal Year 2025

SHANGHAI, April 20, 2026 /PRNewswire/ — Daqo New Energy Corp. (NYSE: DQ) (“Daqo New Energy,” the “Company” or “we”), a leading…
Read More »
MarketersMEDIA Newswire20 April 2026

Online Induction Enhances Workplace Safety with Secure AI Innovation to Support Modern Workforce Management

Sydney, Australia, April 20, 2026 — Online Induction today announced the expansion of its digital onboarding and compliance platform with…
Read More »
Business Wire20 April 2026

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer

Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and…
Read More »
Business Wire20 April 2026

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer

Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and…
Read More »
Business Wire20 April 2026

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer

Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and…
Read More »
Cision PR Newswire20 April 2026

Continuous Composites Expands Manufacturing Footprint to Support Production-Relevant CF3D Systems

COEUR D’ALENE, Idaho, April 20, 2026 /PRNewswire/ — Continuous Composites announced today that it has relocated its operations to a new facility…
Read More »
Cision PR Newswire20 April 2026

Continuous Composites Expands Manufacturing Footprint to Support Production-Relevant CF3D Systems

COEUR D’ALENE, Idaho, April 20, 2026 /PRNewswire/ — Continuous Composites announced today that it has relocated its operations to a new facility…
Read More »

Previous page Next page